2007
DOI: 10.1016/j.athoracsur.2007.01.067
|View full text |Cite
|
Sign up to set email alerts
|

Proposed Modification of Nodal Status in AJCC Esophageal Cancer Staging System

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

2
64
1
3

Year Published

2008
2008
2017
2017

Publication Types

Select...
10

Relationship

0
10

Authors

Journals

citations
Cited by 94 publications
(70 citation statements)
references
References 18 publications
2
64
1
3
Order By: Relevance
“…This convergence likely reflects more aggressive treatment allocated to stage IIB-III patients than to patients with less advanced disease, resulting in comparable 5-y survival. Furthermore, the 5-y survival of patients with PET/CT stage IIB-III disease was 38% in our study, which is superior to that previously reported by other groups (9%-34% for stage IIB and 6%-16% for stage III) (1,29,30). It is also substantially superior even when compared with the reported relative survival rate for patients diagnosed with nodal disease in the Surveillance Epidemiology and End Results database (18.4%) (2).…”
Section: Discussioncontrasting
confidence: 47%
“…This convergence likely reflects more aggressive treatment allocated to stage IIB-III patients than to patients with less advanced disease, resulting in comparable 5-y survival. Furthermore, the 5-y survival of patients with PET/CT stage IIB-III disease was 38% in our study, which is superior to that previously reported by other groups (9%-34% for stage IIB and 6%-16% for stage III) (1,29,30). It is also substantially superior even when compared with the reported relative survival rate for patients diagnosed with nodal disease in the Surveillance Epidemiology and End Results database (18.4%) (2).…”
Section: Discussioncontrasting
confidence: 47%
“…18 F-fluoro-2-deoxyglucose positron emission tomography (FDG-PET) or combined FDG-PET/CT may be of additional value in the detection of distant metastases [6,7]. EUS, CT, and FDG-PET(/CT) are of relatively limited value, however, in the detection of locoregional lymphnode involvement [3][4][5][6][7], whereas the presence and number of lymph-node metastases are important independent predictors for the likelihood of developing systemic disease and long-term survival [3], and the presence of lymph-node metastases may require neoadjuvant chemotherapy or chemoradiotherapy [8]. Furthermore, although EUS combined with fine-needle aspiration (FNA) of suspicious lymph nodes may currently be the most accurate preoperative method for determining nodal status, it is invasive and cannot be performed in the area of the primary tumor because of the risk of tumor seeding [3,9].…”
Section: Introductionmentioning
confidence: 98%
“…Controversy exists about the implications of positive CLNs. Some clinicians exclude these patients for curative treatment options, whereas others believe that these patients are still eligible for surgery [5][6][7]. Multi-modality treatment has been suggested by some [8][9][10][11][12], but the optimal treatment remains unclear due to the paucity of clinical studies and lack of randomized trials.…”
Section: Introductionmentioning
confidence: 95%